Secondary endpoint utilization and publication rate among phase III oncology trials
Secondary endpoint utilization and publication rate among phase III oncology trials
Secondary endpoints (SEP) provide crucial information in the interpretation of clinical trials, but their features are not yet well understood. Thus, we sought to empirically characterize the scope and publication rate of SEPs among late-phase oncology trials. We assessed SEPs for each randomized, published phase III oncology trial across all …